Results 41 to 50 of about 760 (154)
Advanced Science, Volume 12, Issue 33, September 4, 2025.This review comprehensively examines the applications of protein three‐dimensional structures and artificial intelligence in investigating drug synergistic and antagonistic effects. The research findings provide compelling evidence for the precision treatment of cancer and metabolic diseases, thereby promoting the development of personalized medicine ...
Anqi Lin +11 more
wiley +1 more source
Re: Potent in vitro activity of sulbactam-durlobactam against NDM-producing Escherichia coli including cefiderocol and aztreonam-avibactam-resistant isolates : author's response [PDF]
Authors' reply to : Veeraraghavan B, Walia K, Egli A. Re: 'Potent in vitro activity of sulbactam-durlobactam against NDM-producing Escherichia coli including cefiderocol and aztreonam-avibactam-resistant isolates' by Poirel et al.
Le Terrier, Christophe +2 more
core +1 more source
Resistance to sulbactam/durlobactam in carbapenem-resistant Acinetobacter baumannii in treatment-naive setting: in vitro data and genomic insights from Italian bloodstream isolates [PDF]
Objectives: This study evaluated the in vitro activity of sulbactam/durlobactam and comparators against carbapenem-resistant Acinetobacter baumannii (CRAB) bloodstream isolates from Italy and investigated genomic mechanisms underlying resistance. Methods:
Boattini, Matteo +6 more
core +1 more source
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 45, Issue 6, Page 386-392, June 2025.Abstract Introduction Treatment of infections in patients with burn injuries is challenging due to altered antimicrobial pharmacokinetics. Continuous infusion β‐lactam therapy may be a useful antimicrobial stewardship strategy to improve pharmacodynamic target attainment in this population.
Jay D. Olivet +8 more
wiley +1 more source
A review of antibiotic safety in pregnancy—2025 update
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 45, Issue 4, Page 227-237, April 2025.Abstract Antibiotics constitute the majority of prescriptions for women during pregnancy. Common bacterial infections, including urinary tract infections, skin and soft tissue infections, and upper and lower respiratory tract infections, are expected in pregnancy, similar to the general public.
Johny Nguyen +8 more
wiley +1 more source
Novel agents in development for multidrug-resistant Gram-negative infections: potential new options facing multiple challenges. [PDF]
, 2022 PURPOSE OF REVIEW: To review novel antiinfective agents in development for multidrug-resistant (MDR) Gram-negative bacterial infections. RECENT FINDINGS: Four novel agents are in various phases of development (tebipenem, durlobactam-sulbactam, cefepime ...
Arya, Radhika +2 more
core
Synthesis and Evaluation of Carbapenem/Metallo‐β‐Lactamase Inhibitor Conjugates
ChemMedChem, Volume 19, Issue 21, November 4, 2024.We report the synthesis and evaluation of molecular conjugates that combine a carbapenem antibiotic (meropenem or ertapenem) with a recently reported indole carboxylate scaffold. These hybrids are potent inhibitors of metallo‐β‐lactamases including the clinically relevant NDM‐1 and IMP‐1 enzymes.
Mei‐Ling Gao +5 more
wiley +1 more source
Sulbactam-durlobactam combination therapy for carbapenem-resistant Acinetobacter baumannii sepsis with cutaneous involvement in an infant with acute monocytic leukemia: A case report [PDF]
Carbapenem-resistant Acinetobacter baumannii (CRAb) causes severe infections and poses significant treatment challenges. Sulbactam-durlobactam (SUL-DUR) is a novel antibiotic, but its use in children and infants has not been reported.
Rong Yang +5 more
core +1 more source
Health Science Reports, Volume 7, Issue 9, September 2024.Abstract Purpose Infections caused by Acinetobacter baumannii, particularly those resistant to antibiotics such as carbapenem, have become a global health crisis with a significant mortality rate. Hospital‐acquired pneumonia (HAP) and ventilator‐associated pneumonia (VAP) resulting from the A.
Ayush Anand +13 more
wiley +1 more source
Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review
British Journal of Pharmacology, Volume 181, Issue 11, Page 1553-1575, June 2024.Abstract In 2023, seventy novel drugs received market authorization for the first time in either Europe (by the EMA and the MHRA) or in the United States (by the FDA). Confirming a steady recent trend, more than half of these drugs target rare diseases or intractable forms of cancer.
Andreas Papapetropoulos +16 more
wiley +1 more source